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Regulatory T (Treg) cells safeguard against autoimmunity and
immune pathology. Because determinants of the Treg cell fate are
not completely understood, we have delineated signaling events
that control the de novo expression of Foxp3 in naive peripheral
CD4 T cells and in thymocytes. We report that premature termi-
nation of TCR signaling and inibition of phosphatidyl inositol
3-kinase (PI3K) p110, p110, protein kinase B (Akt), or mammalian
target of rapamycin (mTOR) conferred Foxp3 expression and Treg-
like gene expression profiles. Conversely, continued TCR signaling
and constitutive PI3K/Akt/mTOR activity antagonised Foxp3 induc-
tion. At the chromatin level, di- and trimethylation of lysine 4 of
histone H3 (H3K4me2 and -3) near the Foxp3 transcription start site
(TSS) and within the 5 untranslated region (UTR) preceded active
Foxp3 expression and, like Foxp3 inducibility, was lost upon
continued TCR stimulation. These data demonstrate that the PI3K/
Akt/mTOR signaling network regulates Foxp3 expression.
Specialized cell types in multicellular organisms are defined bydistinct patterns of gene expression (1). During their differ-
entiation from hematopoietic stem cells, developing T cells
undergo progressive restriction of their lineage potential. After
the CD4/CD8 lineage choice in the thymus, CD4 lineage cells
remain able to adopt a naive or regulatory cell fate, and naive
CD4 T cells can opt for a range of Th lineages or, alternatively,
become regulatory T (Treg) cells after activation (2, 3). The
choice of Th lineage is important for effective immune responses
to specific pathogens, and the balance between effector and
regulatory cells is critical to ensure immune competence while
avoiding immune pathology and autoimmunity. Thymus-derived
Treg cells are generated via a TGF independent pathway that
requires costimulatory signals (2–4) and typically express the
signature transcription factor Foxp3, which confers regulatory T
cell function (7–10). Differences between the TCR repertoires of
conventional and regulatory CD4 T cells attest to the importance
of MHC/peptide recognition and TCR signaling in conventional
versus regulatory T cell differentiation (11, 12). Adaptive Treg
cells can arise from naive peripheral CD4 T cells, for example by
immunisation with low dose antigen and limited costimulation
(13). TGF is a potent inducer of Foxp3 expression in vitro (14)
and in vivo (15–17) and immunosuppressive drugs, such as
rapamycin (18–20), act by as yet undefined mechanisms to
induce Foxp3 expression (18) or to expand preexisting Treg cells
(19, 20). To clarify the determinants of the Treg cell fate choice,
we set out to identify signaling events that control Foxp3
expression. We show that activation of CD4 lineage thymocytes
and peripheral T cells confers competence for the de novo
expression of Foxp3 in a pathway that is independent of TGF
and is instead controlled by phosphatidyl inositol 3 kinase
(PI3K), protein kinase B (Akt), and mammalian target of
rapamycin (mTOR). The competence for Foxp3 induction is
limited by TCR stimulation itself, and continued stimulation
results in the loss of permissive chromatin modifications from
the Foxp3 TSS and 5 UTR.
Results
Premature Withdrawal of TCR Signals and Inhibitors of the PI3K/mTOR
Pathway Induce Foxp3 Expression in Activated CD4 T Cells. Naive
CD62LhiCD4CD25 LN T cells were isolated by flow cytom-
etry and labeled with CFSE. Residual Foxp3 expression was
minimal as judged by intracellular staining (Fig. 1a, post sort)
and remained unchanged after 18 h of activation with plate
bound anti-TCR and anti-CD28 (Fig. 1a, 18h anti-TCR, anti
CD28) and after another 36 h with anti-TCR (Fig. 1 a–d, with
TCR signaling). However, Foxp3 RNA and protein were mark-
edly up-regulated when the same cells were activated for 18 h
with plate bound anti-TCR and anti-CD28 and then maintained
without TCR stimulation for 36 h (Fig. 1 a–d, no TCR signaling).
Hence, the continued availability of TCR signals appeared to
control Foxp3 expression in newly activated CD4 T cells. TCR/
CD28 engagement triggers multiple signaling pathways (21). To
investigate which of these control Foxp3 expression, we screened
small molecule inhibitors of enzymes involved in signal trans-
duction. No increase in Foxp3 expression was seen when inhib-
itors of calcineurin/NFAT (cyclosporin A and FK-506), mitogen
activated kinases (SB203580, PD98059), protein kinase-C
(UCN-1028c, calphostin C, Myr-N-FARKGALRQ-NH2,
Go¨6976, Ro-32-0432, Ro-31-8220), glycogen synthase kinase-3
(SB21673), PPAR (GW501516), and -secretase/Notch (L-
685458; data not shown) were added to 18 h activated CD4 T
cells. By contrast, the PI3K inhibitor LY294002 potently induced
Foxp3 in this assay (Fig. 1 a–c, LY). Rapamycin, an inhibitor of
the protein kinase mTOR, which lies in the same signaling
pathway (25), also induced Foxp3 (Fig. 1 a–c, rapa). The
combination of LY294002 and rapamycin induced Foxp3 in
75% of CD4 T cells (Fig. 1 a–c, rapaLY) and synergized with
TGF, resulting in 90% Foxp3 induction in the absence of
exogenous cytokines (Fig. 1 a–c, TGFrapaLY). CFSE
labeling ruled out the selective expansion of preexisting Foxp3
cells (Fig. 1a), and cell counts showed a substantial net increase
in Foxp3 cell numbers (Fig. 1c).
De novo induction of Foxp3 by PI3K and mTOR inhibitors was
formally demonstrated by using AND TCR transgenic Rag1/
CD62LhiCD4CD25 LN T cells, which are devoid of preexisting
Foxp3 cells [Fig. 1d and supporting information (SI) Fig. S1a].
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Activation with peptide-pulsed antigen presenting cells also con-
ferred competence for Foxp3 induction by PI3K inhibitors (Fig.
S1b).
TCR/CD28 activation followed by PI3K/mTOR inhibition
induced Foxp3 not only in peripheral CD4 T cells, but also in
CD4CD8CD25 thymocytes (Fig. 1e).
Differential Role of p110 Isoenzymes in Foxp3 Regulation. Selective
PI3K isoenzyme inhibitors have recently been characterized at
the biochemical, structural, and biological level (22–25) (Table
S1). We utilized such compounds to define the role of specific
PI3K catalytic subunits in Foxp3 regulation. TGX115 did not
affect Foxp3 expression at concentrations that selectively inhibit
p110 (0.1 M; 23), indicating that p110 does not control
Foxp3 in this setting. Similarly, the p110 inhibitor AS-605240
induced Foxp3 expression only at concentrations far in excess of
those required to inhibit p110 (0.008 M; ref. 22 and Fig. 1f ).
IC-87114 is highly selective for p110 (23) and induced Foxp3 in
10–15% more cells than TCR deprivation alone, demonstrating
a contribution of p110 to the regulation of Foxp3. PI-103
strongly induced Foxp3 at concentrations below its in vitro IC50
for mTOR (0.02 M) and around the in vitro IC50 for p110
(0.008 M) (23). PIK90 strongly induced Foxp3 at 0.1 M (Fig.
3a), where it inhibits p110 (and p110, which did not induce
Foxp3; see above). Higher concentrations of PI-103 and PIK90
affect p110 (23), but Foxp3 induction by PI-103 and PIK90
exceeded that of full p110 inhibition by IC-87114 (Fig. 1f ).
These data identify p110 as a dominant isoenzyme and the
hierarchy of p110    / may set Foxp3 regulation apart
from lymphocyte activation, where p110 appears dominant
(25, 26).
TCR Signaling and the PI3K/Akt/mTOR Network. Protein kinases of
the Akt/PKB family are components of the PI3K/Akt/mTOR
Fig. 1. TCR signal deprivation and inhibitors of the PI3K/mTOR pathway induce Foxp3 expression in newly activated CD4 T cells. (a) Naive CD62LhiCD4CD25
LN T cells were isolated by flow cytometry, labeled with CFSE, and activated for 18 h with anti-TCR and anti-CD28. After this, the cells were cultured for 36 h under
various conditions: with plate-bound anti-TCR (with TCR signaling); without anti-TCR (no TCR signaling); and with the PI3K inhibitor LY294002 (LY, 10 M), the
mTOR inhibitor rapamycin (rapa, 25 nM), and/or TGF (1 ng/ml). Foxp3 expression was assessed by intracellular staining. (b) Naive CD4 T cells were activated for
18 h as in a and then cultured for 36 h with anti-TCR (with TCR signaling) or without anti-TCR (no TCR signaling). The expression of Foxp3 RNA was assessed by
real time RT-PCR (mean SD, n 3). (c) Naive CD4 T cells were activated for 18 h and aliquots of 105 cells (input) were transferred to the conditions described
in a. After 36 h, cells were counted, and Foxp3 expression assessed by intracellular staining. Bars show the percentage (red) and the number (black) of Foxp3
cells. (d) AND TCR transgenic Rag1/ CD62LhiCD4CD25 LN T cells were activated for 18 h as in a and then cultured for 36 h with anti-TCR (with TCR signaling);
without anti-TCR (no TCR signaling); and with LY294002 (LY, 10 M), rapamycin (rapa, 25 nM), or TGF (1 ng/ml). See Fig. S1 for percentages and numbers of
Foxp3 cells. (e) CD4CD8CD25 thymocytes were activated for 18h as in a and then cultured for 36 h with anti-TCR (control) or with LY294002 and rapamycin
without anti-TCR (LYrapa). ( f) Naive CD4 T cells were activated for 18 h as in a and cultured for 36 h with the indicated PI3K inhibitors without anti-TCR. The
percentage of Foxp3 cells is shown after subtracting Foxp3 cells generated in cultures without anti-TCR (mean SD, n 4–12). The p110 isoform specificity
of each inhibitor is summarized in Table S1. (g) Naive CD4 T cells were activated for 18 h and cultured for 36 h with plate-bound anti-TCR (control) or with the
allosteric Akt inhibitor Akti1/2 (0.3 M) without anti-TCR.
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network, and their activity is regulated by PI3K via PDK1 and
by one of the two known mTOR-containing complexes,
mTORC2 (27). We treated activated CD4 T cells with the
allosteric Akt inhibitor Akti-1/2 (28) and found Foxp3 induction
at concentrations around its IC50 for Akt1 and Akt2 (58 nM and
210 nM, respectively). This shows that inhibition of Akt and PI3K
and mTOR can drive Foxp3 induction (Fig. 1g).
T cell activation results in the sustained activation of the
PI3K/Akt/mTOR network (21), reflected in the phosphorylation
of S6 ribosomal protein (pS6), a direct target of the mTOR-
regulated p70 S6 kinase S6K1 (27). Intracellular staining showed
that TCR/CD28 signaling (but not anti-CD28 alone) induced
and maintained high levels of pS6 (Fig. 2a). Upon withdrawal of
TCR antibody from 18 h activated T cells, S6 phosphorylation
declined only gradually (Fig. 2b; confirmed by immunoblotting
in Fig. 2b Inset). LY294002 and rapamycin abrogated S6 phos-
phorylation much more rapidly (Fig. 2b), correlating with their
ability to enhance Foxp3 induction.
Constitutive Activation of the PI3K/Akt/mTOR Network Antagonises
Foxp3 Induction. Phosphatase and tensin homologue deleted on
chromosome 10 (PTEN) is the major negative regulator of the
PI3K/Akt signaling pathway, and its loss results in constitutive
Akt activity (29). To test the concept that PI3K/Akt/mTOR
signaling controls Foxp3, we compared the inducibility of Foxp3
in TCR/CD28 activated PTEN-deficient and control T cells (29)
in response to the classical Foxp3 inducer TGF versus PI3K
inhibitors. The frequency of TGF-induced Foxp3 cells was
considerably lower in PTEN-deficient than in control CD4 cells,
but the PI3K inhibitor LY294002 restored Foxp3 induction in
PTEN-deficient CD4 T cells (Fig. 2c). These data add genetic
evidence that PI3K/Akt/mTOR signaling controls Foxp3 expres-
sion in activated T cells.
PI3K/mTOR Inhibitors Induce Treg-Like mRNA and microRNA Expres-
sion Profiles. To address whether Foxp3 was induced in isolation or
as part of a Treg-like transcriptional program, we performed cDNA
expression arrays 24 h after PI3K/mTOR inhibition. Comparison
with control activated T cells showed that, in addition to Foxp3,
numerous Treg cell markers were up-regulated, including IL2ra
(3.0x), Il2rb (3.0x), and Ctla4 (2.9x) and members of the suppressor
of cytokine signaling (Socs) family Socs1 (3.1x), Socs2 (8.3x), and
Socs3 (10.5x). As expected from a Treg-like progam, the lympho-
kine transcripts Il2, Ifng and IL3 were strongly down-regulated
(112x, 56x, and 7.8x, respectively). Next, we compared PI3K/mTOR
inhibitor-induced cells and freshly isolated Treg cells with naive
CD4 T cells and found substantial coregulation: More than half of
the transcripts up-regulated in Treg cells were also up-regulated in
Foxp3-induced cells (775 of 1376, 56%). Evenmore strikingly, 87%
(1,243 of 1,431) of transcripts thatwere down-regulated inTreg cells
were also down-regulated in response to PI3K/mTOR inhibition
(Fig. 3a). Functional annotation showed that up-regulated tran-
Fig. 2. TCR signaling controls the expression of Foxp3 via PI3K/mTOR/Akt. (a) Naive LN CD4 T cells were stimulated with anti-TCR and anti-CD28 for 1 or 18 h
or for 1 h with anti CD28 alone (no TCR signaling). S6 phosphorylation was determined by intracellular staining. (b) Naive LN cells were activated as in a. After
18 h, rapamycin (25 nM) or LY294002 (10 M) were added for 1 h, or the cells were cultured for the indicated time in the absence of anti-TCR. pS6 levels were
determined as in a. (Inset) Immunoblotting confirmed declining pS6 in response to TCR signal deprivation, rapamycin, and LY294002. (c) (Top) PTEN-deficient
and control CD4 T cells were depleted of preexisting Treg cells and activated with anti-TCR/CD28. (Middle) TGF (0.3 ng/ml) was added, and Foxp3 expression
was assessed 48 h later. (Bottom) As a control, the PI3K inhibitor LY294002 was added and cells were deprived of TCR signaling after 18 h of activation.
Fig. 3. PI3K/mTOR inhibition initiates a Treg-like transcriptional program in
newly activated T cells. (a) Gene expression differences between Treg cells
versus naive CD4 T cells and in 24 h PI3K/mTOR inhibitor-treated cells versus
naive CD4 T cells. Shown are the numbers of up- and down-regulated tran-
scripts and the intersection of expression differences between Treg and Foxp3
induced cells. (b) Functional annotation of coregulated transcripts in Treg cells
and Foxp3 induced cells relative to naive CD4 T cells, using DAVID. (c) mi-
croRNA expression by Treg cells and Foxp3 induced cells compared by qPCR.
miR-142-3p and miR-21 are shown as examples for Treg-like and non-Treg-like
microRNA expression by Foxp3 induced cells. The expression profiles of eight
other microRNAs are listed.
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scripts were enriched for processes of cellular, macromolecular and
primary metabolism, cell division, and cell cycle and for the
functional terms nucleotide binding, electron transporter, and
kinase regulatory activity. Down-regulated transcripts represented
distinct processes, in particular transcriptional regulation. Only a
minority of genes that were coregulated in ex vivo Treg cells and
Foxp3 induced cells were known genomic targets of Foxp3 (Fig.
S2). MicroRNAs are important mediators of posttranscriptional
gene regulation and naive CD4 T cells and Treg cells express
distinct microRNAs (31). Of the 10 microRNAs we profiled, 7
showed Treg-like expression in Foxp3-induced cells (Fig. 3c).
Taken together, our analysis suggests that PI3K/mTOR signaling
controls not only Foxp3 and its direct targets, but a wider Treg-like
transcriptional progam (30).
No Detectable Involvement of TGF in Foxp3 Induction by PI3K and
mTOR Inhibitors. Because TGF is a powerful inducer of Foxp3
expression (14–17) and synergizes with PI3K/mTOR inhibitors
(Fig. 1), we addressed its requirement in this system. TGF binding
induces phosphorylation of receptor-associated Smad2 and Smad3,
providing a sensitive indicator of TGF signaling. pSmad2 (S465/
467) was readily detectable in cells exposed to TGF (Fig. 4a lane
1) but not in cells subjected to TCR signal deprivation (Fig. 4a, lane
2) or PI3K and mTOR inhibition (Fig. 4a, lanes 3 and 4). Neutral-
izing TGF antibodies and the Smad kinase inhibitor SB 431542
(32) blocked Foxp3 induction by TGF, but did not affect Foxp3
induction by PI3K/mTOR inhibitors (Fig. 4b). Hence, TGF ap-
pears dispensable for Foxp3 induction by TCR signal deprivation
and PI3K/mTOR inhibition.
Histone Modifications Mark a Window of Opportunity for Foxp3
Induction by PI3K and mTOR Inhibition. T cell activation was re-
quired for Foxp3 induction, and Foxp3 inducibility was maximal
in T cells activated for 18 h before PI3K/mTor inhibition. Earlier
addition of inhibitors blocked activation (ref. 19 and data not
shown), and Foxp3 induction was inefficient at later time points
(Fig. 5 Top Left). Hence, the competence for Foxp3 expression
induced by activation of CD4 T cells is transient and continued
TCR signaling antagonises Foxp3 inducibility.
The expression of the Foxp3 locus is intimately linked to its
chromatin structure (33, 34). Permissive posttranslational histone
modifications are found in Treg cells at the Foxp3 promoter, the
intronic differentially metylated region 3 (DMR3), and the recently
described 2079 to 2198 enhancer (33–35). To explore how
continued TCR signaling reduces the competence of CD4 T cells
to express Foxp3, we considered that chromatin marks can provide
important information not only about the actual expression, but
also the potential for the expression of developmentally regulated
loci (36). We used ChIP (chromatin immunoprecipitation) to
analyze histone modifications at the Foxp3 locus in male (XY) cells
(Foxp3 is X-linked). We compared CD4 cells activated for 18 h
(high potential for Foxp3 induction, no Foxp3 expression) to the
same cells after 72 h of TCR stimulation (reduced potential for
Foxp3 induction, no Foxp3 expression) and CD4 cells activated for
18 h and then exposed to PI3K/mTOR inhibitors (high Foxp3
expression). Oct4, which is silent in T cells, and the actively
transcribed Ikzf1 (Ikaros) locus served as controls (Fig. 5). Inter-
estingly,H3K4 di- and trimethylationwas found near theFoxp3TSS
(34) and the 5 UTR not only in Foxp3 cells but also in 18-h
activated CD4 T cells, which had the potential for Foxp3 induction
but did not actually express Foxp3. In contrast, H3K4me2 and -3
were lost after 72 hof continuousTCRsignaling (Fig. 5). These data
Fig. 4. No apparent TGF involvement in Foxp3 induction by PI3K and mTOR inhibitors. (a) Naive LN CD4 T cells were activated for 18 h in serum-free AIM-V
medium and then exposed to TGF (1 ng/ml, 90 min, lane 1); TCR signal deprivation (90 min, lane 2); or TCR signal deprivation, rapamycin, and LY294002 (90
min for lane 3, 8 h for lane 4). Blots were sequentially probed with anti-pSmad2 (S465/467) and anti-Smad2/3. (b) Naive LN CD4 T cells activated as in a were
deprived of TCR signals and TGF, and PI3K/mTOR inhibitors were added as indicated. Cultures were supplemented with neutralizing anti TGF (3 g/ml) or the
Smad kinase inhibitor SB431542. Foxp3 expression in the presence of anti TGF (dark gray bars) or SB431542 (light gray bars) was determined 2 days later and
normalized to control cultures (black).
Fig. 5. Inducibility of Foxp3 by PI3K and mTOR inhibition is transient, and H3K4
methylation at the Foxp3 TSS and 5 UTR marks the inducible state. Naive CD4 T
cells were activated for the indicated time with anti-TCR and anti-CD28 and then
cultured for 36 h with LY294002 and rapamycin (Upper Left). Naive CD4 T cells
(black), Treg cells (white), naive CD4 T cells activated for 18 h (orange) or 72 h
(green)or inducedtoexpressFoxp3byPI3K/mTORinhibitors (red)wereexamined
for H3K4me2 and H3K4me3 by ChIP and qPCR near the Foxp3 TSS (295 to105)
and within the 5 UTR (4505 to4621 and6144 to6280). Primer positions
are indicated (34). pOct4 and pIkzf1 are shown as controls.
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link H3K4 methylation to the potential for Foxp3 expression.
Conversely, the TCR signaling-induced loss of this permissive
chromatin mark correlates with declining competence for Foxp3
expression.
Discussion
We have shown that TCR signaling via PI3K p110, p110, Akt,
and mTOR controls Foxp3 expression in activated CD4 lineage
thymocytes and peripheral T cells. Inhibition of this signaling
network conferred de novo expression of Foxp3 and Treg-like
mRNA and miRNA profiles. Conversely, constitutive activation of
the PI3K/AKT/mTOR network in PTEN-deficient T cells reduced
Foxp3 inducibility, which was restored by PI3K inhibition. Foxp3
induction by TCR signal deprivation and PI3K/mTOR inhibition
shares features with the development of natural Treg cells. TGF,
although synergistic, is not required for the induction of Foxp3
expression in the thymus (8, 9) or in response to TCR signal
deprivation and PI3K and mTOR inhibition (this article), and both
are markedly enhanced by costimulatory signals (refs. 2 and 3 and
Fig. S3). Whereas CD28 signals can interfere with adaptive Treg
differentiation driven by TGF (e.g., 13, 17), cooperation between
TGF and CD28 was reported for the Foxp3 enhancer element at
2079 to 2198 (35).
Evidence for an involvement of the PI3K/Akt/mTOR network in
Treg differentiation and function has been accumulating: Treg cell
numbers increase in the thymi of PI3K p110-deficient mice (37),
rapamycin can promote Treg cell differentiation in specific settings
(18–20), and exciting data published while this manuscript was
under review indicate that Akt signaling interferes with Foxp3
expression in vitro and in vivo (38). Our data provide a rationale for
these genetic and pharmacological data by demonstrating that (i)
TCR signaling controls Foxp3 expression via a signaling network
with the key components PI3K and , Akt, and mTOR, the
mammalian target of rapamycin, and (ii) the timing of PI3K/Akt/
mTOR inhibition relative to TCR signaling is critical for the
outcome. Interestingly, Akt signaling appears to be compromised in
a PTEN-dependent fashion in established Treg cells (39).
Directing cell fate choice in the immune system by pharmaco-
logical means is potentially attractive, and a growing number of
suitable compounds are approved for clinical use. The ability of
small molecule inhibitors to block PI3K/mTOR/Akt signaling tem-
porarily rather than permanently may be beneficial because con-
stitutive p110 deficiency promotes the differentiation of Treg cells
in the thymus, but impairs their subsequent maintenance in the
periphery (26, 37).
In our experiments, the duration of TCR signaling affects the
probability of Foxp3 induction. Weak TCR signals and limited
costimulation had been linked to Foxp3 induction (13, 17, 40). We
find higher Foxp3 induction rates by optimal anti-TCR/CD28
signaling followed by TCR signal deprivation and PI3K/mTOR
inhibition, consistent with a recent two-stage model of Treg dif-
ferentiation inwhichTCRsignals are required for the up-regulation
of genes like Cd25 that predispose to Treg differentiation, but not
for the subsequent induction of Foxp3, which occurs in the absence
of additional TCR signals (41). Treg development can result from
the recognition of tissue-specific antigens expressed by thymic
medullallary epithelium (42). Such antigens are expressed in a
mosaic fashion (43) and may therefore induce transient rather than
sustained TCR signals, which in turn could contribute to the
outcome of Foxp3 induction versus negative selection. Our data
further show that continued TCR signaling extinguishes the com-
petence for Foxp3 induction in naive CD4 T cells. ChIP analysis
identified H3K4me2 and -3 near the Foxp3 TSS and within the 5
UTR as a mark for the inducibility of Foxp3, because these
permissive histone modifications were induced by the activation of
naive CD4 T cells and persisted upon the induction of Foxp3
expression, but declined in parallel with the loss of Foxp3 induc-
ibility in response to continued TCR signaling. The challenge now
is to understand how signaling, transcription factors, and chromatin
components cooperate to translate the duration of TCR signaling
into a determinant of Treg cell fate choice.
Materials and Methods
Cell Sorting and Culture. Animal work was done under the Animals (Scientific
Procedures) Act, U.K. Lymph node (LN) cells or thymocytes from wild-type
(C57BL/6, BALB/c, or C57BL/6 129) AND TCR transgenic (44)Rag1/or lckCre
Ptenlox/lox mice (29) were sorted by flow cytometry as described in ref. 31. LN
CD4 CD25 CD62Lhi T cells or CD4 CD8CD25 thymocytes were activated
with plate bound anti-TCR (H57; 200 ng/ml; PharMingen) and anti-CD28 (2
g/ml, PharMingen). AND TCR transgenic cells were also activated with B10.BR
antigen presenting cells and pigeon cytochrome-C peptide 81–104 (44). Intra-
cellular staining for Foxp3 protein was done as advised by the manufacturers
(eBiosciences). Anti-pS6 Ser-235/236 (Cell Signaling; catalog no. 2211) was
used with the eBioscience Foxp3 staining kit and anti rabbit IgG-FITC or
IgG-Cy5 (Jackson ImmunoResearch).
RT-PCR, Northern Blot Analysis, and Immunoblotting. Total RNA was isolated by
using RNA-Bee (Tel-Test) and reverse transcribed. Real-time PCR analysis was
normalized to the geometric mean of Ywhaz and Ube2L3 as described in ref.
31. The following primer sequences were used:Ywhaz, CGTTGTAGGAGCCCG-
TAGGTCAT (forward), TCTGGTTGCGAAGCATTGGG (reverse); Ube2L3, AG-
GAGGCTGATGAAGGAGCTTGA (forward); TGGTTTGAATGGATACTCTGCT-
GGA (reverse); and Foxp3, ACTCGCATGTTCGCCTACTTCAG (forward);
GGCGGATGGCATTCTTCCAGGT (reverse). Immunoblotting was performed as
described in ref. 31. Quantitative real-time RT-PCR of miRNAs used gene
specific RT primers and TaqMan MicroRNA Assay Mix (Applied Biosystems) as
described in ref. 31.
Chromatin Immunoprecipitation.ChIP was done as described in ref. 45, using 20
g of chromatin mixed with 80 g of Drosophila S2 chromatin with 2.5 l of
anti-H3K4me2 (Upstate; catalog no. 07-030), anti-H3K4me3 (Abcam; catalog
no. ab8580-100), or rabbit anti mouse IgG (Dako Cytomation; catalog no.
Z0259). The following primer sequences (5 to 3): Foxp3 295 to 105 (TSS;
numbering according to ref. 34) CATTGATACCTTTTACCTCTGTGGTG (for-
ward), GTGTGTGCTGATAATTGCAGGGT (reverse); Foxp3, 5 UTR 4505 to
4621 (DMR3) GTTGTGACAACAGGGCCCAG (forward), CACTGTCTGTT-
GGGGCGTTC (reverse); Foxp3, 5 UTR 6144 to 6280 (exon-1) CAACTTCTC-
CTGACTCTGCCTTCA (forward), GGAACTGTGCTAGTGGGAAGTGTACT
(reverse); pOct4 GTGAGCCGTCTTTCCACCAGG (forward), GGGTGAGAAGGC-
GAAGTCTGAA (reverse); and pIkzf1 CCAGTTTCAGGGACTCGGCT (forward),
TCGGGGAACACGGGACAC (reverse).
Gene ExpressionArrays and Bioinformatics Analysis.Affymetrix mouse genome
430 2.0 arrays were used in duplicate. Analysis was done in Bioconductor,
using robust multi array normalization (www.bioconductor.org). Individual P
values were corrected according to Benjamini and Hochberg (46). Only tran-
scripts with both an adjusted P value 	0.05 and a fold-change of 1.5 were
considered differentially expressed. Functional annotation used DAVID
(http://david.abcc.ncifcrf.gov).
ACKNOWLEDGMENTS. We thank Eugene Ng for cell sorting and Drs. James
Elliott, Rose Zamoyska, Chris Rudd, and Patrick Maxwell for discussions and
the CSC Microarray Facility for array hybridizations. This work was supported
by the Medical Research Council (U.K.).
1. Fisher AG (2002) Cellular identity and lineage choice. Nat Rev Immunol 2:977–
982.
2. Fontenot JD, Rudensky AY (2005) A well adapted regulatory contrivance: Regulatory T cell
development and the forkhead family transcription factor Foxp3.Nat Immunol 6:331–337.
3. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25CD4 regulatory T cells
in immunological tolerance to self and non-self. Nat Immunol 6:345–352.
4. Marie JC, Letterio JJ, Gavin M, Rudensky AY (2005) TGF-1 maintains suppressor function
and Foxp3 expression in CD4CD25 regulatory T cells. J Exp Med 201:1061–1067.
5. Brunkow ME, et al. (2001) Disruption of a new forkhead/winged-helix protein, scurfin,
results in the fatal lymphoproliferative disorder of the scurfy mouse.NatGenet 27:68–73.
6. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the
transcription factor Foxp3. Science 299:1057–1061.
7. Fontenot JD, Gavin MA, Rudensky AY (2003) FoxP3 programs the development and
function of CD4CD25 regulatory T cells. Nat Immunol 3:330–336.
8. Fontenot JD, et al. (2005) Regulatory T cell lineage specification by the forkhead
transcription factor FoxP3. Immunity 22:329–341.
Sauer et al. PNAS  June 3, 2008  vol. 105  no. 22  7801
IM
M
U
N
O
LO
G
Y
9. Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for scurfin in
CD4CD25 T regulatory cells. Nat Immunol 3:337–342.
10. Tran DQ, Ramsey H, Shevach EM (2007) Induction of FOXP3 expression in naive human
CD4FOXP3 T cells by T-cell receptor stimulation is TGF dependent but does not
confer a regulatory phenotype. Blood 110:2983–2990.
11. Hsieh CS, Zheng Y, Liang Y, Fontenot JD, Rudensky AY (2006) An intersection between
the self-reactive regulatory and nonregulatory T cell receptor repertoires. Nat Immu-
nol 7:401–410.
12. Pacholczyk R, et al. (2007) Nonself-antigens are the cognate specificities of Foxp3
regulatory T cells. Immunity 27:493–504.
13. Kretschmer K, et al. (2005) Inducing and expanding regulatory T cell populations by
foreign antigen. Nat Immunol 6:1219–1227.
14. Chen W,et al. (2003) Conversion of peripheral CD4CD25- naive T cells to CD4CD25
regulatory T cells by TGF- induction of transcription factor Foxp3. J Exp Med
198:1875–1886.
15. Coombes JL, et al. (2007) A functionally specialized population of mucosal CD103DCs
induces Foxp3 regulatory T cells via a TGF and retinoic acid dependent mechanism.
J Exp Med 204:1757–1764.
16. Sun CM, et al. (2007) Small intestine lamina propria dendritic cells promote de novo
generation of Foxp3 T reg cells via retinoic acid. J Exp Med 204:1775–1785.
17. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ (2007) All-trans retinoic acid
mediates enhanced T reg cell growth, differentiation, and gut homing in the face of
high levels of co-stimulation. J Exp Med 204:1765–1774.
18. Gao W, et al. (2007) Contrasting effects of cyclosporine and rapamycin in de novo
generation of alloantigen-specific regulatory T cells. Am J Transplant 7:1722–1732.
19. Battaglia M, Stabilini A, Roncarolo MG (2005) Rapamycin selectively expands
CD4CD25FoxP3 regulatory T cells. Blood 105:4743–4748.
20. Mantel PY, et al. (2006) Molecular mechanisms underlying FOXP3 induction in human
T cells. J Immunol 176:3593–3602.
21. Kane LP, Weiss A (2003) The PI-3 kinase/Akt pathway and T cell activation: Pleiotropic
pathways downstream of PIP3. Immunol Rev 192:7–20.
22. Camps M, et al. (2005) Blockade of PI3Kgamma suppresses joint inflammation and
damage in mouse models of rheumatoid arthritis. Nat Med 11:936–943.
23. Knight ZA, et al. (2006) A pharmacological map of the PI3K family defines a role for
p110alpha in insulin signaling. Cell 125:733–747.
24. Foukas LC, et al. (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase
in growth and metabolic regulation. Nature 441:366–370.
25. Bilancio A, et al. (2006) Key role of the p110delta isoform of PI3K in B-cell antigen and
IL-4 receptor signaling: Comparative analysis of genetic and pharmacologic interfer-
ence with p110delta function in B cells. Blood 107:642–650.
26. Okkenhaug K, et al. (2002) Impaired B and T cell antigen receptor signaling in
p110delta PI 3-kinase mutant mice. Science 297:1031–1034.
27. Sabatini DM (2006) mTOR and cancer: Insights into a complex relationship. Nat Rev
Cancer 6:729–734.
28. Barnett SF, et al. (2005) Identification and characterization of pleckstrin-homology-
domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385:399–408.
29. Hagenbeek TJ, et al. (2004) The loss of PTEN allows TCR alphabeta lineage thymocytes
to bypass IL-7 and Pre-TCR-mediated signaling. J Exp Med 200:883–894.
30. Hill JA, et al. (2007) Foxp3 transcription-factor-dependent and -independent regula-
tion of the regulatory T cell transcriptional signature. Immunity 27:786–800.
31. Cobb BS, et al. (2006) A role for Dicer in immune regulation. J ExpMed 203:2519–2527.
32. Inman GJ, et al. (2002) SB-431542 is a potent and specific inhibitor of TGF- superfamily
type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Phar-
macol 62:65–74.
33. Floess S, et al. (2007). Epigenetic control of the Foxp3 locus in regulatory T cells. PLoS
Biol. e38.
34. Kim HP, Leonard WJ (2007) CREB/ATF-dependent T cell receptor-induced FoxP3 gene
expression: A role for DNA methylation. J Exp Med 204:1543–1551.
35. Tone Y, et al. (2008) Smad3 and NFAT cooperate to induce Foxp3 expression through
its enhancer. Nat Immunol 9:194–202.
36. Spivakov M, Fisher AG (2007) Epigenetic signatures of stem-cell identity.Nat RevGenet
8:263–271.
37. Patton DT, et al. (2006) The phosphoinositide 3-kinase p110delta is critical for the
function of CD4CD25Foxp3 regulatory T cells. J Immunol 177:6598–6602.
38. Haxhinasto S, Mathis D, Benoist C (2008). The AKT-mTOR axis regulates de novo
differentiation of CD4Foxp3 cells. J Exp Med 205:565–574.
39. Walsh PT, et al. (2006) PTEN inhibits IL-2 receptor-mediated expansion of CD4CD25
Tregs. J Clin Invest 116:2521–2531.
40. So T, Croft M (2007) Cutting edge: OX40 inhibits TGF-- and antigen-driven conversion
of naive CD4 T cells into CD25Foxp3 T cells. J Immunol 179:1427–1430.
41. Lio CW, Hsieh CS (2008) A two-step process for thymic regulatory T cell development.
Immunity 28:100–111.
42. Aschenbrenner K, et al. (2007). Selection of Foxp3 regulatory T cells specific for self
antigen expressed and presented by Aire medullary thymic epithelial cells. Nat
Immunol 8:351 358.
43. Anderson MS, et al. (2005) The cellular mechanism of Aire control of T cell tolerance.
Immunity 23:227–239.
44. Kaye J,etal. (1989) Selective development of CD4T cells in transgenic mice expressing
a class II MHC-restricted antigen receptor. Nature 341:746–749.
45. Baxter J, et al. (2004) Histone hypomethylation is an indicator of epigenetic plasticity
in quiescent lymphocytes. EMBO J 23:4462–4472.
46. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and
powerful approach to multiple testing. J Roy Stat Soc B 57:289–300.
7802  www.pnas.orgcgidoi10.1073pnas.0800928105 Sauer et al.
